Form 4: BioAge Labs CFO Dov Goldstein Acquires 170,000 Stock Options
SEC Form 4 Filing
BioAge Labs' Chief Financial Officer, Dov Goldstein, reports the acquisition of 170,000 stock options in the company.
Summary
- On February 18, 2025, Dov A. Goldstein, the Chief Financial Officer of BioAge Labs, Inc., acquired 170,000 stock options.
- The exercise price of these options is $4.38.
- The options vest monthly, with 1/48th of the total award vesting each month starting February 1, 2025, contingent upon continued service to BioAge Labs.
- The options expire on February 17, 2035.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, and the acquisition of stock options by an executive is generally viewed as neutral to slightly positive, indicating confidence in the company's future.
Positives
- The acquisition of stock options by the CFO aligns his interests with those of the shareholders, incentivizing him to work towards the company's success.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- Shareholders may view the acquisition of stock options by the CFO as a positive sign, aligning his interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 02/01/2025 | First tranche of stock options vests. |
| 02/18/2025 | Date of stock option acquisition. |
| 02/20/2025 | Date of signature on the Form 4 filing. |
| 02/17/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.